| --- | --- | --- | |---------------------------------------------|-------|-------| | Click Here to Edit Title | | | | | | | | | | | | Second Quarter 2024 Earnings August 1, 2024 | | | | | | | Trusted Solutions, Improving Lives™ Cautionary Statement Click Here to Edit Title 2 Cautionary Statement Under the Private Securities Litigation Reform Act; Non-GAAP Measures This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-10235 IDEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 36-3555336 (State or oth ...

For further information: TRADED: NYSE (IEX) EX-99.1 Investor Contact: Wendy Palacios Vice President FP&A and Investor Relations (847) 498-7070 IDEX REPORTS SECOND QUARTER RESULTS AND UPDATES 2024 OUTLOOK Second Quarter 2024 Highlights (All comparisons are against the second quarter of 2023 unless otherwise noted) • Sales of $807 million, down 5% overall and 4% organically • Reported diluted EPS of $1.86, up 2%, and adjusted diluted EPS of $2.06, down 6%, exceeding second quarter expectations • Operating cas ...

IDEX Corporation's (IEX) second-quarter 2024 adjusted earnings of $2.06 per share surpassed the Zacks Consensus Estimate of $2.04. The bottom line decreased approximately 6% from the year-ago quarter's earnings of $2.18 per share. However, it exceeded management's projection of $2.00-$2.05 per share. Revenue Details IDEX's net sales of $807.2 million missed the Zacks Consensus Estimate of $831 million. The top line also decreased 5% year over year. Organic sales decreased 4% year over year. Foreign currency ...

Idex (IEX) came out with quarterly earnings of $2.06 per share, beating the Zacks Consensus Estimate of $2.04 per share. This compares to earnings of $2.18 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 0.98%. A quarter ago, it was expected that this maker of the Jaws of Life device and other engineered products would post earnings of $1.75 per share when it actually produced earnings of $1.88, delivering a surprise of 7.43% ...

IDEX Corporation (IEX) is scheduled to release second-quarter 2024 results on Jul 31, after market close. The Zacks Consensus Estimate for second-quarter earnings has remained steady in the past 60 days. The company has an impressive earnings surprise history, having outperformed the consensus estimate in each of the preceding four quarters, the average surprise being 6.3%. The consensus estimate for revenues is pegged at $830.8 million, indicating a decline of 1.8% from the year-ago quarter's reported figu ...

Image Source: Zacks Investment Research Expansion Efforts: The company solidified its product portfolio and leveraged business opportunities through asset additions. Acquired assets boosted its sales by 1% in the first quarter of 2024. In December 2023, IDEX acquired advanced material science solutions provider STC Material Solutions. This acquisition expanded its expertise in material sciences and offered significant opportunities to collaborate with other IDEX-critical components businesses on comprehensi ...

The board of directors of IDEX Biometrics ASA has resolved to issue 13,207,430 incentive subscription rights to 56 employees and individual contractors in the IDEX Biometrics group. The grant was made under the company's 2024 incentive subscription rights plan as resolved at the annual general meeting on 16 May 2024. The exercise price of the subscription rights is NOK 1.45 per share. The SRs vest by 1/3 per year over three years. The SRs expire on 16 May 2029. Following the company's recent restructuring i ...

Nordroden/iStock via Getty Images I highlighted IDEX's (NYS)E:IEX) weak growth in Health & Science Technologies segment in my previous coverage published in February 2024. The company released its Q1 FY24 result on April 23rd and reaffirmed its full-year guidance. While I acknowledge that the Health & Science Technologies will continue to face challeneys in FY24, IDEX's order growth has already started to moderate. I reiterate 'Buy' rating with a fair price target of $220 per share. Order Moderation In Q1 F ...

AuthenTrend, based out of Taiwan, focuses on digital document and identity verification. With a global reach and a strong presence in Asia, AuthenTrend provides a new generation of fingerprint-enabled card type security keys – ATKey.Card NFC x Surface Pro 10. These biometric cards support both contact and contactless FIDO2 passwordless login and take the login experience to the next level – secure and seamless. AuthenTrend provides FIDO2-certified biometric access card solutions to consumers and enterprises ...